Blood Lipopolysaccharide (LPS) Rifaximin Study

Clinical trial NCT02124512 · COMPLETED

Trial details

NCT number: NCT02124512
Sponsor: Philip Kern
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Obese Insulin Resistance Metabolic Syndrome

Start date: 2015-03-01
Primary completion: 2019-05-31
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.